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Objective: This field trial aimed to assess the effect of a multivalent clostridial and Pasteurella vaccine 
(Heptavac P Plus, MSD Animal Health, 2015), administered to lambs at two different time points, on lamb 
mortality (primary outcome), morbidity and growth rates (secondary outcomes) as compared to unvaccinated 
lambs. 
 
Background: This veterinary practice-based study was motivated by a knowledge gap identified during flock 
health planning activities and engagement between veterinarians and commercial sheep producers in a 
regional knowledge exchange programme in South West England. Common queries to the veterinary practice 
from sheep producers during summer to autumn 2012 included the value and timing of vaccinations to 
prevent disease associated with pasteurellosis. Discussions between veterinarians and consultants working in 
preventive sheep flock health planning stimulated a scientific literature search, which highlighted the lack of 
published data on field vaccine testing of Pasteurella components under British sheep commercial farming 
systems, and a lack of strong evidence in order to inform practical questions regarding the optimal timing of 
vaccinations aimed at preventing lamb mortalities in the pre-, peri- and post-weaning periods.  
 
Evidentiary value: A field vaccine trial was conducted on six commercial sheep flocks in South West England. 
From April 2013, across the six farms a total of 900 twin-born lambs (Ovis aries) were systematically randomly 
allocated into 1. unvaccinated, 2. early- (6 to 8-week-old) or 3. late- (18 to 20-week-old) vaccination groups. 
The study provides evidence to support recommendations for sheep producers regarding risks for clostridial 
disease in fully unvaccinated sheep flocks, supports the benefits of preventive ewe vaccination, and indicates 
that pre-weaning vaccination of lambs may be beneficial for reducing peri- and post-weaning losses on some 
flocks. The study highlights the challenges of identifying the reasons for mortality in grazing lambs, and 
provides new evidence to support the need for early intervention and treatment of ocular lesions in young 
lambs, in order to reduce their negative impact on lamb performance.  
 
Methods. During the 6-month trial, lambs were assessed for ocular lesions, orf lesions, clinical respiratory 
disease, lameness, diarrhoea, and ear tag losses. Monthly liveweights (kg) and mortalities were recorded. 
Lambs were removed from the study when they reached producer-defined finishing objectives, ≥46 kg 
liveweight or when they died. 
 
Results: Overall, low levels of mortality and disease outcomes were observed in both control and vaccinated 
lambs. A mortality rate of 33 deaths per 1000 lambs at-risk, 0.8% lameness (95% CI 0.6–1.1), 1.7% diarrhoea 
(95% CI 1.4–2.2), 3% ocular disease (including ocular discharge and/or entropion) (95% CI 2.2–3.2), and 2.6% 
orf lesions (95% CI 2.2–3.1) were recorded over the trial period. A higher proportion of mortalities occurred in 
unvaccinated or partially vaccinated lambs (n=23; 76.7%), as compared to trial lambs that had received a 
primary vaccine course (n=7; 13.3%). A small proportion of mortalities (n=3; 10.0%) occurred in lambs whose 
vaccination status could not be confirmed No clinical signs of respiratory disease were recorded during 
veterinary or producer assessments of control or vaccinated trial lambs. Mixed-effects models found 
significant between-farm and time differences in liveweights (p<0.001) but no significant effect of vaccination 
status on lamb growth rates. A dramatic decrease in lamb growth rates across all farms coincided with the 
weaning period – this was also the period in the study were the majority of grazing lamb mortalities were 
identified in flocks that routinely vaccinated their ewes against clostridial disease and pastuerellosis. 
 
Conclusion: A clear trend was found with fewer mortalities occurring in lambs that received a multivalent 
clostridial and Pastuerella spp. vaccination course compared to unvaccinated lambs. The reasons behind 
mortalities in grazing lambs were not diagnosed given the low submission of carcases for veterinary necropsy 
examination that was attributed to carcase scavenging and decomposition. No significant effects of 
vaccination were found on lamb growth rates or clinical outcomes. However, a secondary finding was the 






Vol 5, Issue 1 
DOI:  10.18849/VE.V5I1.244 
 




aged 6 weeks and over – supporting the need for early recognition and intervention in order to reduce animal 
welfare and production impacts. 
 
Application: We highlight study findings, field experiences and discuss some of the practical challenges and 
considerations in design and conduct of field vaccine trials used to inform evidence-based veterinary practice. 
The study will be of interest to veterinary surgeons, sheep producers, flock health and agricultural consultants, 
pharmaceutical agencies and advisors, researchers and those engaged in applied studies in animal health and 
welfare, veterinary epidemiology, preventive health management researchers, and participants and advisors in 




Clostridial diseases and pasteurellosis are endemic diseases of sheep and reported to be among the most 
common causes of mortality in growing lambs (Lewis, 2007). Clostridia are commensals of the gastrointestinal 
tract (Uzal, 2004) and are found widely in both soil and water sources (Al Saif and Brazier, 1996), whilst 
Mannheimia haemolytica and Bibersteinia trehalosi are commensals of the ovine upper respiratory tract of 
healthy sheep (Donachie, 2007). Clostridial disease and pasteurellosis are both believed to be caused by 
‘stressor’ or ‘trigger’ factors, such as sudden weather changes, abrupt dietary change or movement, all of 
which can facilitate rapid bacterial multiplication, toxin production and commensal tissue invasion. Disease 
outbreaks are frequently unpredictable, and progression can be so rapid that they present as ‘sudden deaths’ 
(Donachie, 2007). 
 
Both experimental and field research studies have identified that multivalent vaccines provide sheep with 
effective Clostridia spp. antibody responses (Brown et al., 1976; Wells et al., 1984; and Green et al., 1987). 
Consequently, prophylactic flock vaccination is considered to be key to clostridial disease control and 
prevention. Mortalities associated with clostridial diseases are most frequently reported in unvaccinated 
sheep flocks or in those not fully adhering to recommended vaccination regimes (Lewis, 2007). In comparison 
to the evidence supporting clostridial spp. vaccination, there is much weaker evidence regarding the 
Pasteurella component efficacy. The efficacy of Pasteurella spp. vaccination was originally tested in laboratory 
challenge studies on experimentally-infected, specific-pathogen-free lambs (Gilmour et al., 1979; Wells et al., 
1979: Jones et al., 1989). No effect of a combined Pasteurella spp. vaccine was found on the level of 
pneumonic lesions found in lambs when compared to unvaccinated control lambs (Chandrasekaran et al., 
1991). Similarly, field vaccination of Bighorn ewes following a pneumonia outbreak with either an 
experimental Birbersteinia trehalosi and M. haemolytica vaccine or a commercial Pasteurella multocida and M. 
haemolytica bovine vaccine provided no beneficial effect on neonatal lamb survival (Cassirer et al., 2001). 
Furthermore, field research into an ovine Pasteurella vaccine on commercial New Zealand flocks identified no 
significant differences in lung lesion scores between vaccinated and unvaccinated lambs (Goodwin-Ray et al., 
2008). The lack of proven field efficacy of commercially available Pasteurella spp. ovine vaccines in New 
Zealand has stimulated experimental research into the cross-protective efficacy of a subcutaneously 
administered M. haemolytica S1 strain (Zheng et al., 2015). Development of effective vaccines to prevent 
pasteurellosis appears to be challenging given the interplay between bacteria, including Pasteurella spp. with 
Mycoplasma spp. and viruses that commonly occur (Malone et al., 1988). 
 
 Currently, strong evidence regarding field efficacy and immunity derived from M. haemolytica and B. trehalosi 
components of multivalent Clostridia and Pasteurella vaccines as tested in British commercial sheep 
production systems is lacking. This study, therefore, aimed to capture novel field data to inform veterinary 
flock health planning, specifically regarding best practice administration and timing of vaccinations aimed at 
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METHODS & MATERIALS 
 
Inclusion criteria           
  
A convenience sample of six sheep flocks in North Devon, England (clients located within a 15 mile radius of 
Torch Farm and Equine Ltd., South Molton, a veterinary practice) were recruited. Farms eligible for this study 
were commercial spring-lambing flocks with a minimum of 250 breeding ewes producing either slaughter 
lambs or breeding replacements (Table 1); that were not currently vaccinating lambs against Clostridia spp. or 
Pasteurella; and had a history of sudden death in lambs with confirmed or suspected pasteurellosis (based on 
prior veterinary diagnostic investigations including post-mortem examination). Prior to enrolment, the 
veterinarian (MJG) and researcher (CJP) visited farms to gather background data on flock management, 
disease control practices, and to assess eligibility criteria. Informed and written producer consent was 
obtained. Farms were provided with a study protocol, and a mortality and treatment recording book.  
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In the absence of any known prevalence data, sample size estimates were based on prior veterinary 
knowledge of diseases in the recruited flocks and ability of the study to detect an assumed 3% difference in 
mortality (primary outcome) and morbidity (secondary outcome) between early and late vaccinated lambs. 
Sample size calculations assumed that the minimum level of mortality was 3%, the assumed relative risk of 
disease in the unvaccinated group was 3: the Type 1 error probability was set at α = 5% and the power of the 
study was (1-β) = 80%. This required a sample size of 243 individuals in each group, giving a total of 486 lambs. 
To maintain disease challenge and reduce the possible effect of confounding from protection afforded by early 
vaccinated lambs, a further group of lambs was included in the trial and remained unvaccinated as per 
standard farm policy. One farm that had been recruited unexpectedly dropped out shortly before study 
commencement, and, as a consequence, a later lambing flock that met the eligibility criteria was recruited 
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To limit the impact of further farm drop-out or unexpected disease outbreaks, a slightly larger than estimated 
sample size was included. Accordingly, a total of 900 twin lambs of various breeds (Table 1) aged between 6 
and 8 weeks (based on peak lambing dates) were enrolled into the trial.  
 
Study design 
Heptavac P Plus (MSD Animal Health, 2015) is marketed as a preventive vaccine for reducing flock mortalities 
and morbidity associated with seven specific clostridial diseases and for the control of pneumonic 
pasteurellosis (M. haemolytica) in lambs from a minimum age of 3 weeks, and in the control of systemic 
pasteurellosis (Bibersteinia trehalosi) in weaned fattening and breeding sheep (MSD Animal Health, 2015). The 
objective of the field trial was to assess the effect of this multivalent Clostridia spp. and Pasteurella vaccine 
administered to lambs from six commercial sheep flocks at early (6 to 8 weeks old) or late post-weaning (18-20 
weeks old) vaccination time points on lamb mortality (primary outcome), morbidity and growth rate 
(secondary outcomes).  
 
To reduce within-farm genetic, management and nutritional effects, only twin lambs were included. The 
sample comprised 112 entire rams (12.4%), 322 castrated ram (35.7%) and 466 ewe (51.8%) lambs of a variety 
of breeds presented by the producer (Table 1). Systematic random allocation of trial lambs into either 
unvaccinated, early or late (post-weaning) vaccination groups was applied by the researcher (CJP) according to 
the order that the lambs walked into the handling race. Lambs were not matched on sex or breed.  
 
At visit 1, lambs were individually ear tagged by the producer. Due to limited study resources and aims to keep 
lambs managed as per the usual routines of each farm, producers inserted their regular ear tag of choice. 
Whilst the selection of tag brand was not part of the study design, with the exception of farm 3, single tagging 
and the same tag brand was used on all farms. At each visit, lambs were firstly individually examined for six 
standardised clinical descriptors (Table 2). The same experienced veterinarian (MJG) performed examinations 
on all farms, and remained blinded to data captured from other study visits. Lambs were assessed whilst 
moving and standing in the handling race, prior to entering the weighing crate and before vaccination. At each 
visit, farm weighing scales were calibrated before individual liveweight data (kg) capture. The researcher 
maintained data entry.  
 
On each farm, all trial lambs (including early and late vaccinated lambs and unvaccinated lambs) were 
managed as a single management group until weaning, when they were separated into two same-sex 
management groups. Trial lambs were managed as a separate group and did not graze with other (non-trial) 
lambs on the farm from the period of study, enrolment to end. Lambs were selected for slaughter according to 
producer preference for weight, carcase conformation and fat class; if selected prior to the study visit, lambs 
were weighed the day before slaughter by the producer.  
 
All vaccinations were performed by the same veterinary surgeon following manufacturer (MSD, 2015 and best 
practice guidelines on vaccine storage and administration industry (RUMA, 2006). As illustrated in Fig. 1, lambs 
were vaccinated with a primary course of Heptavac P Plus at two time points: ‘early’ (first vaccine 
administered when lambs were approximately 6 to 8 weeks-old) and ‘late’ (first vaccine administered when 
lambs were approximately 18 to 20-weeks-old). Primary vaccination consisted of two doses (2 ml) of Heptavac 
P Plus injected subcutaneously 5–10 cm below the ear using a sterile vaccination system (Sterimatic 
Worldwide Ltd, UK). Dosing interval was 4 to 5 weeks. Vaccine was stored at 4°C and transported to farms in 
insulated cool boxes. Bottles were unopened until just before administration. A new vaccination bottle was 
used for each farm, and once opened, vaccine was used within 2 hours. The veterinarian who administered all 
vaccinations was not blinded to vaccine type or brand. No placebo was used. The researcher sprayed the 
fleece of all trial lambs with a colour mark based on allocation group; colours differed between study farms. 
The veterinarian and producer were not informed of fleece codes. Due to the on-farm nature of the trial and 
their necessary involvement with handling and vaccinating lambs and need for informed consent and 
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maintained mortality and treatment records were collected. Throughout the trial, farms were asked to present 
trial and non-trial lamb mortalities for necropsy examination.  
 
 
Table 2 Standardised clinical descriptors for assessment of lamb health and morbidity (secondary outcome) 
scored on binary scale (absent/present) 
Clinical outcome Assessment criteria 
 
Clinical respiratory signs 
 
Observed signs of mucopurulent nasal discharge, and/or 
persistent severe coughing, and/or dyspnoea and/or, 
tachypnoea 
Facial and oro-nasal orf 
lesionsa 
Observed active and healing facial and oro-nasal orf lesions: 
external lesions, with or without discharging pustules and/or 
associated signs of inflammation; significant swelling and 
hyperaemia, and/or without signs of keratinizationa 
Ocular 
discharge/lesion/entropionb Observed ocular discharge (purulent, or haemorrhagic, or tear 
staining) and/or keratitis, conjunctivitis, and/or corneal ulcer 
and/or entropion 
Ear tag lesion Observed external lesions (abscesses and/or purulent 
discharge and/or tears and/or rips) around site of ear tag 
Lamenessb Observed three-legged gait and/or holding a foot off the 
ground and/or stiff or stilted gait, and/or head-nod associated 
with gait 
Diarrhoeab Observed diffuse faecal perineal soiling 
a Scored as per descriptors of Lovatt et al. (2012) 
b Scored as per descriptors of Phythian et al. (2012) 
 
 
Trial time schedule is illustrated in Fig. 1. Early vaccinated lambs received their first primary dose (aged 
approximately 6 to 8 weeks-old) at visit 1 and the second 1 month later (visit 2). On farms 1 to 5, lambs were 
weaned prior to visit 4; late vaccinated lambs received their first primary dose at visit 4 (approximately 18 to 
20 weeks old) and second dose at visit 5. Due to management constraints and later recruitment, farm 6 lambs 
were weaned just prior to visit 3. Late vaccination was conducted at visits 3 (when lambs were approximately 
16 weeks old) and 4. Due to the early slaughtering of lambs on farm 1, only two late vaccine group lambs 
received the full vaccine course. The study ended on 7 November 2013 before trial lambs reached finishing 
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Figure 1 Schedule of timings for the first (1st) and second (2nd) vaccinations of the primary vaccine course for 
early and late vaccination groups, weaning and the end of trial on each of the six study flocks 
 
Ethical approval 
The study was part of recognised veterinary practice under the Veterinary Surgeons Act of 1966. Ethical 
approval was obtained from the University of Bristol ethics committee (ethical review reference VIN/13/021).  
 
Statistical analysis 
Data was entered into Excel (Microsoft Office) and analysed using Stata version 13 (Statacorp, Texas). Based 
on the study start date, study age (days) was assigned for each weight-recording session. Since these 
commercial farms had slightly different finishing goals, if lambs had not already left the trial, the exclusion 
criteria and final visit liveweight was set as ≥46 kg. Descriptive statistics explored the number of lambs, and 
proportion of mortality, morbidity, tag losses, and liveweights on each farm at each study period. One-way 
analysis of variance (ANOVA) examined for significant differences in mean liveweight of each group at study 
entry, in order to assess for any systematic bias in allocation. Differences in overall mortality rates between 
vaccinated and unvaccinated trial lambs were examined for significance using Wilcoxon signed-rank (paired) 
test. Growth rates (daily liveweight gain – DLWG, g/day) were calculated between successive paired visits as: 
difference in weight/number of days between successive weighings. Overall, mean trial lamb DLWG (W0) was 
calculated as: (last recorded weight minus weight on visit 1 / number of days in trial)*1000. Mean difference in 
liveweight gain (kg) between unvaccinated and early vaccinated lambs was examined from visit 1 up to visit 4 
(weaning) using paired t-tests. Statistical significance testing was set at p≤0.05. 
 
Data modelling was supported by a statistician (PJC) blinded to vaccine status. Firstly, using mixed effects 
multilevel linear regression models including farm identity and visit number (1 to 6) as fixed effects to assess 
the effect of vaccination status (unvaccinated, early or post-weaning vaccination) on mortality, liveweight and 
DLWG. The continuous predictor ‘study age’ was also forced into all models to assess the effect of vaccination 
status on DLWG. No significant interaction terms were identified. Later, farm identity was included as a 
random effect, as individual lamb identity was nested within farm. Visit period (1 to 6) was also examined as a 
random effect. Residuals were modelled in an autoregressive structure with an order of one. Effect of 
lameness, ocular condition, orf lesion, diarrhoea or ear tag lesion on liveweight were analysed in separate 
mixed-effects regression models.  
 
During analysis, farm 1 lambs originally allocated into the late group but that were not vaccinated were 
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reached finishing objectives/exclusion criteria. Therefore, two datasets – 1. entire dataset of all six farms and 
2. dataset with removal of farms 1 and 6 – were compared to assess for significant differences in study 
findings.  
 
To assess the effect of vaccination up to the point of weaning (i.e. early vaccination versus no vaccination), 
lambs originally allocated to the late vaccination group were recoded as unvaccinated. Fixed and mixed-effects 
multilevel linear regression models, as described above, were used to identify any differences between 





With the exception of farm 1, all other study flocks had at least a 5 year history of prophylactic administration 
of multivalent combined clostridial and Pasteurella vaccine (Heptavac P Plus, MSD Animal Health, 2015) to 
breeding animals (primary course and a booster 4 to 6 weeks prior to expected peak lambing date). No flocks 
had administered multivalent clostridial or Pasteurella vaccines to pre-weaned lambs in the previous 5 years. 
All lambs were routinely tail-docked using rubber rings within the first week of life and, except for farm 6, 
routinely castrated with rubber rings. On farm 5, all lambs routinely received a live orf vaccine (Scabivax Forte, 
MSD Animal Health, 2015) prior to turnout onto pasture. Trial lambs received oral anthelmintics, on average 
five times (range 4–6) during the trial period. Farm 1 employed a rotational grazing system; farm 2 moved 
stock every 3 days, whilst farms 3 to 6 used set-stocking. On all farms, trial lambs were maintained as a single 
management group. On each farm, all trial lambs were grazed together as a single management group until 
weaning, when male and female trial lambs were separated and managed as two same-sex trial groups. Farm 
1 provided creep feeding for lambs from visit 1; farms 2 to 5 provided supplementary creep feed from weaning 
onwards; and farm 6 provided no concentrates during the study. 
 
Animals 
Between 23 April and 7 November 2013, the number of lambs assessed per visit decreased over time, 
reflecting cumulative effects of mortalities (Table 3 and Table 4), exclusion of three sick lambs between visits 4 
and 5 (fractured limb, blind, and recumbent) and lambs reaching finishing or exclusion criteria from visit 3 
onwards. Overall, 72 tag losses (8.0%) were recorded (Table 3). Due to double ear-tagging on farm 4, only 52 
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Table 3 Number of lambs recruited, recorded ear tag losses, lamb mortalities, earliest and latest finishing 





































time from trial 
entry 
 (study age) 
Farm 1 135 21 (15) 7 (5.2) 7 (100)  0 (0) 0 (0) 56 days 40 148 days 
Farm 2 135 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 90 days 41.5 154 days 
Farm 3 135 36 (26.7) 4 (3.0) 2 (50.0) 2 (50.0) 0 (0) 122 days 43 155 days 
Farm 4 135 5 (3.7) 7 (5.2) 6 (85.7) 0 (0) 1 (14.3)  125 days 42 154 days 
Farm 5 135 4 (3.0) 3 (2.2) 2 (66.7) 0 (0)  1 (33.3)  99 days 42.4 162 days 
Farm 6 225 6 (2.7) 9 (4.0) 6 (66.7) 2 (33.3) 1 (11.1) d d d 
Total 900 72 (8.0) 30 (3.3) 23 (76.7) 4 (13.3) 3 (10.0) 
 
  
a Unvaccinated lambs include those in the unvaccinated trial group and trial animals in early or late vaccination groups 
prior to completion of the primary vaccination course following vaccine datasheet guidance.  
b Trial lambs were considered to be fully vaccinated two weeks following the correct administration of the primary 
vaccine course) in adherence with vaccine datasheet guidance. 
c Due to timing of death occurring between visit dates and lack of an exact dead date it is unclear whether early vaccine 
group lambs were fully vaccinated according to datasheet guidance at the time of death. 




A total of 30 mortalities (3.3%) were recorded in trial lambs, which was equivalent to a study mortality rate of 
33 deaths per 1000 lambs at-risk. Ear tags were retrieved by producers from 14 trial lamb carcases and 
presented to the researcher, allowing full confirmation of the individual lamb identity in these cases. For the 
remaining mortalities, trial group status was identified by examining database records and cross-checking the 
number of lambs at each farm visit. Lambs were presumed dead if they were missing on at least two 
consecutive visits, and had not been slaughtered. This approach permitted confirmation of the group and 
vaccination status of all but three mortalities (Table 3). 
 
Mortalities arose in both vaccinated and unvaccinated trial lamb groups (Table 3). A clear trend was found 
with a higher level of lamb losses recorded in unvaccinated lambs, compared to lambs that were considered to 
be fully vaccinated (p=0.052). Overall, farms 1 and 4 experienced the highest levels of trial lamb mortality 
(5.2%). On farm 1, all mortality cases occurred in unvaccinated lambs or before primary vaccine course 
completion. Due to the lack of an exact death date for some lambs, it was not possible to confirm whether 
three trial lambs in the early vaccinated group were considered to be fully vaccinated (Table 3). Overall, 14 
trial lambs died pre-weaning and 16 trial lambs died in the period post-weaning. There was some between-
farm variation in the timing of lamb deaths. All trial lamb losses (n=7) on farm 1 occurred from early June to 
early July, i.e. before weaning (Fig. 1), although lambs on this farm were receiving concentrate feed at their 
time of death. By contrast, there were two main periods for the timing of lamb losses (n=23) on farms 3–6. 
Deaths of grazing lambs on farms 3–6 mainly occurred in the week of and up to 1 month post-weaning (16/23, 
69.6%), i.e. late July to late August. The remainder of trial deaths on farms 3–6 occurred pre-weaning and were 
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The reasons for mortalities in trial lambs was not fully elucidated due to the very low number (n=2) of animals 
presented for veterinary post-mortem examination; both lamb carcases examined came from a single study 
flock. On farm 1, one trial lamb from the unvaccinated group (approximately 4 months old) was presented for 
necropsy on 13 June 2013 at the veterinary practice, and an unvaccinated non-trial lamb (coinciding with 
reported ‘sudden deaths’ in eight non-trial lambs), was necropsied on 28 June 2013 (MJG) during a trial farm 
visit. Both lambs were in good body condition. Gross post-mortem findings in the trial lamb included the 
presence of blood-tinged frothy fluid present in the trachea and congestion of both lung lobes with frothy 
fluid. The thymus surface and thoracic fat surface were petechiated, pericardial capillaries were inflamed and 
generalised petechiation of the pericardium with haemorrhage on the internal surface of left ventricular wall 
was observed. Gross findings of the non-trial lamb included tracheal hyperaemia, petechiation of diaphragm, 
sub-capsular renal petechiation, fibrinous pericarditis, and liquid small intestinal content. No further diagnostic 
testing was performed. 
 
Morbidity 
No adverse events associated with vaccine administration were recorded. No clinical respiratory disease was 
recorded during repeated assessments. Relatively low mean levels of lameness, signs of diarrhoea, ocular 
discharge/entropion and orf lesions were recorded (Table 4). No significant effect of ear or orf lesions on 
DLWG were found. Orf was not observed on farms 4 and 6, nor in lambs that had received orf vaccination at 
pasture turnout (farm 5). Whilst entire ram lambs had heavier liveweights than ewe lambs (p<0.001), no 
significant interaction was found between sex and clinical outcomes. Compared to unaffected peers, those 
with signs of lameness or entropion/ocular discharge or diarrhoea were lighter (p<0.001).  
 
 
Table 4 Number (n) and percentage (%) of trial lambs observed with specific clinical signs (secondary outcome) 
at each visit period on six sheep flocks 
Clinical 
outcome Score 
n (%) lambs observed across all farms with each outcome at each visit (n=6) Total n (%) lambs 





851 (94.6) 872 (99.4) 860 (97.6) 776 (95.2) 725 (98.1) 411 (99.8) 4513 (97.0) 
Discharge 25 (2.8) 11 (1.24) 20 (2.27) 27 (3.31) 10 (1.35) 1 (0.24) 94 (2.0) 





898 (99.8) 849 (95.7) 867 (98.4) 811 (99.5) 736 (99.6) 411 (99.8) 4590 (98.7) 
Ripped or torn 0 (0) 2 (0.2) 6 (0.7) 4 (0.5) 2 (0.3) 1 (0.3) 15 (0.3) 
Infection or 
abscess 
2 (0.2) 36 (4.1) 8 (0.9) 0 (0) 1 (0.1) 0 (0) 47 (1.0) 
Diarrhoea 
Absent 881 (97.9) 883 (99.6) 861 (97.7) 800 (98.2) 720 (97.4) 408 (99.0) 4571 (98.3) 
Present 19 (2.1) 4 (0.4) 20 (2.3) 15 (1.8) 19 (2.57) 4 (0.97) 81 (1.7) 
Orf 
Not observed 888 (98.7) 782 (88.2) 874 (99.2) 815 (100) 739 (100) 412 (100) 4521 (97.4) 
Active or healing 
lesion 
12 (1.3) 104 (11.6) 7 (0.8) 0 (0) 0 (0) 0 (0) 123 (2.7) 
Gait 
Sound 899 (99.9) 887 (100) 880 (99.9) 808 (99.1) 723 (97.8) 399 (96.8) 4592 (98.7) 




Trial group liveweights at study entry (visit 1) were not significantly different and showed no evidence of 
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Table 5 Mean, standard deviation (SD) and range (min–max) in liveweight (kg) of unvaccinated, early and late 




Mean liveweight varied between farms (Table 5). Mean finishing weight (farms 1 to 5) was 44.9 kg. The trial 
ended before lambs on farm 6 reached finishing weights. Mean DLWG generally decreased over time (W1 to 
W5), particularly after weaning and prior to visit 4 (Table 6). Mean time from study entry to finishing was 116 
days (95% CI 112–120 days); i.e. on average lambs reached slaughter weight at 6 months old. Farm identity 
and visit period had a significant effect on liveweight (p<0.001). When the full dataset and dataset excluding 
farms 1 and 6 were examined, and when farm identity, visit number, sex and animal identity were accounted 
for, no significant effect of vaccination on liveweight or DLWG was found. Furthermore, there was no 















V1 V2 V3 V4 V5 V6 
Unvaccinated 
 
n 300 300 299 276 249 135 
Mean liveweight 16.6 25.0 30.3 34.3 37.3 41.8 
SD 3.5 4.3 5.4 5.8 5.9 4.9 
Min–max 7.0–26.5 13–38 11.6–45.0 18.0–48.0 22.0–51.0 25.0–51.5 
Early 
vaccination 
n 300 298 293 269 250 143 
Mean liveweight 16.5 24.5 30.0 33.8 36.2 41.6 
SD 3.2 4.1 5.5 5.7 19.0–49.0 4.8 
Min–max 8.0–25.0 13–27 16.0–46.0 15.0–51.0 6.2 24.0–51.5 
Late 
vaccination 
n 300 289 289 269 240 134 
Mean liveweight 16.4 24.9 30.2 34.5 36.8 41.8 
SD 3.2 4.0 5.3 5.4 6.1 4.7  
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Table 6 Mean, standard deviation (SD) and range (min–max) in daily liveweight gain (DLWG) for consecutive 
weight gained in the time between visits 1 to 2 (W1), visits 2 to 3 (W2), visits 3 to 4 (W3), visits 4 to 5 (W5), 
visits 5 to 6 (W5) and overall DLWG (W0) of trial lambs on six sheep farms 
a Insufficient data for analysis: most lambs finished before visit 6 (Farm 1) or the trial had already ended (Farm 6) 
 
 
To the authors’ knowledge, following a literature search on the subject, no previous studies assessing field 
performance of multivalent Clostridial spp. and Pasteurella vaccines on British sheep flocks have been 
reported. In contrast to the medical sector, veterinary vaccine field trials are often considered inferior to 
challenge trials because of the lack of standardised conditions (Knight-Jones et al., 2014). However, vaccines 
need to perform under farming conditions where variation in individual animal immunity, pathogen exposure 
(Knight-Jones et al., 2014) and environmental and husbandry factors influence disease aetiology (EMEA, 2001). 
Well-designed and well-conducted field trials are necessary for informing evidence-based management of 
livestock (Sanderson, 2006; Dean et al., 2015). 
 
Trial design and conduct 
The Veterinary All Trials initiative (www.vetalltrials.org) supports the open publication of all trial outcomes and 







Farm 1 Farm 2 Farm 3 Farm 4 Farm 5 Farm 6 
W1 
Mean DLWG (g/day)  312.4 372.2 333.4 264.4 252.9 192.0 
SD 54.4 73.0 78.0 58.0 63.5 57.7 
min–max 162.2–459.5 189.7–569.0 71.43–535.7 115.4–423.1 -40.0–393.3 -86.2–362.1 
W2 
Mean DLWG (g/day) 316.8 205.1 242.9 162.2 161.42 85.6 
SD 69.9 69.8 78.2 70.74 85.9 49.5 
min–max 74.1–555.6 55.56–388.9 -35.7–607.1 -112.9–451.6 -214.3–592.9 76.9–307.7 
W3 
Mean DLWG (g/day) 278.6 270.10 212.2 153.9 119.3 64.7 
SD 99.0 76.7 75.1 85.1 61.6 62.5 
min–max 0–466.7 71.4–464.3 -111.11–388.9 -111.1–463.0 -73.17–419.5 -132.4–294.1 
W4 
Mean DLWG (g/day) 182.9 167.4 71.7 190.8 66.6 28.8 
SD 93.4 78.7 64.0 72.3 66.2 82.0 
min–max 40.81–346.2 -42.86–382.4 -68.97–400.0 0–341.5 -137.9–324.1 -177.4–241.9 
W5 
Mean DLWG (g/day) a 184.0 88.5 89.6 150.4 a 
SD a 73.25 68.5 101.08 54.14 a 
min–max a -42.9–328.6 -309.5–312.5 -166.7–344.8 -5.9–270.6 a 
W0 
Mean DLWG (g/day) 309.6 248.6 202.8 181.9 147.8 92.1 
SD 50.2 45.36 69.23 35.49 33.1 27.0 
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and improve the quality of studies used to inform evidence-based decision making (Dean et al., 2015). This 
article serves to highlight trial results, and discuss planned study design and conduct considerations together 
with actual field experiences to inform and improve further studies. A ‘gold standard’ randomised controlled 
trial (RCT) was not feasible due to limited personnel and financial resources. Instead, we used the REFLECT 
guidelines (Sargeant et al., 2010) to inform field trial design, conduct and reporting of study results. Blinding of 
the veterinarian, researcher and producers was performed as far as possible. Due to the nature of veterinary 
practice-based research and the need for producer involvement in animal handling, there were some practical 
limitations. Participants and researchers were not blinded to the treatment administered (i.e. the type or 
brand of vaccine). Producers presented a sample of twin lambs considered representative of the flock. 
Systematic randomisation was performed to reduce introduction of sample selection bias. To reduce observer 
scoring and recall biases, lambs were assessed by the same veterinarian who was blinded to data recorded at 
previous trial visits. To minimise potential measurement errors, farm weighing systems were calibrated at each 
visit, before use. To minimise the effect of competitive maternally-derived antibodies (MSD Animal Health, 
2015), all early vaccine lambs received their first primary vaccine dose aged 6 weeks or above. 
 
Expected ear tag losses in commercial systems were the reason for having both individual and group 
identification methods. The high level of tag losses (26.7%) on farm 3 may reflect the tagging technique, that a 
different brand of tag was used, or fencing type. Fleece colour was sufficient for group identification, and 
colour codes were withheld from the veterinarian and producers. Since fleece marks were clearly visible, trial 
participants were not fully blinded. Up to weaning, all trial lambs on each farm were managed as a single 
group, and post-weaning were managed as a group of trial ewe lambs and a group of trial ram lambs. There 
was no evidence that lambs of different vaccination status were deliberately managed in a different way due 
to incomplete blinding. Limited resources necessitated data entry by the researcher. Modelling, however, was 
supported by a statistician (PJC) blinded to vaccine status.  
 
Generalisability 
Trial farms were considered representative of farms and production types within the practice area and 
represented a convenience sample. Therefore, mortality, liveweight and DLWG data must be interpreted in 
light of the approximate age and timing of visits. Such data cannot be considered representative of all 
commercial English sheep flocks nor should it be used for benchmarking of flocks of a similar production type. 
 
Mortalities and necropsy findings 
The study identified a lower level of mortality in fully vaccinated lambs, however vaccination alone did not 
prevent lamb mortalities. 13.3% (n=4) of trial mortality cases occurred in lambs classed as fully vaccinated, and 
these mostly arose in the early vaccination group. Aside from Farm 1, the majority of grazing lamb losses 
occurred in the week immediately after weaning or in the month following weaning. This timing appears to 
coincide with the period 12–16 weeks after ewe vaccination when colostral antibodies to clostridal spp. are 
purported to wain in lambs which have received adequate passive transfer of immunity from correctly 
vaccinated ewes (MSD Animal Health, 2015). However, due to the very low level of lambs presented for 
necropsy investigations, the causes of death in both vaccinated and unvaccinated trial lambs were not 
diagnosed.  
 
Mortality data capture and necropsy were not undertaken during the field Pasteurella spp. vaccine trial by 
Goodwin-Ray et al. (2008) due to the expected logistical difficulties for accurately monitoring on New Zealand 
flocks. Given the smaller English trial flock sizes in this study, accurate producer-recording of mortalities was 
considered feasible. All flocks were within a 15 mile radius of the veterinary practice, and participating 
producers were offered free-of-charge necropsies. Despite this, only one study flock (farm 1) submitted lambs 
(one trial and one non-trial lamb) for necropsy during the study. The low level of necropsy uptake was 
disappointing. Whilst producers recognised the value of necropsy for informing management decisions, a 
commonly reported issue was the extensive degree of scavenging and carcase decomposition when lambs 
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present trial highlights the real logistical and practical issues with monitoring mortalities in grazing lambs, even 
when recruiting an engaged and committed group of producers to veterinary practice-based research.  
 
A total of 30 mortalities were registered but the lack of individual animal identity and poor recovery rate of ear 
tags from decomposed or scavenged carcases, and the loss of ear tags between visits, particularly on farm 3, 
initially presented some challenges for data analysis. However, since vaccine status was colour coded, applying 
the assumption that lambs missing for at least two visits and not slaughtered had died, these elements 
facilitated confirmation of the vaccination status of nearly all mortality cases. On farm 1, where no multivalent 
Clostridia spp. or Pasteurella preventive ewe vaccination was historically undertaken, all trial lamb deaths 
occurred pre-weaning in either unvaccinated lambs, or in partially vaccinated lambs prior to completion of 
their primary vaccination course. Sudden deaths of prime lambs that were near to reaching slaughter weight 
were reported on farm 1, but did not occur in the trial lamb group. Necropsies on farm 1 revealed gross signs 
suggestive of pasteurellosis, and enterotoxaemia due to Clostridium perfringens D toxin (colloquially: ‘pulpy 
kidney’). Further investigations, including bacteriology, brain histology and epsilon toxin testing, required for 
definitive diagnosis of clostridial enterotoxaemia (Uzal et al., 2004) were not conducted due to limited study 
resources. Therefore, these diseases and other causes of septicaemia could not be excluded.  
 
Lambs on farm 1 may have been at a higher risk of clostridial disease and pasteurellosis prior to weaning since 
they were offered creep feeding throughout the trial period, whereas on farms 2–4 – where creep feeding was 
offered post-weaning – the change in diet and stress associated with weaning may explain the higher number 
of lambs that died post-weaning. Evidence from this study and earlier clinical reports (Lewis, 2007) support the 
value of preventive ewe vaccination as a means of reducing lamb mortality on farm 1 associated with 
preventable disease. Lamb losses or clinical signs (respiratory disease) associated with Pasteurella spp. were 
not definitively diagnosed in any of the trial groups, which may reflect the very low level of necropsy 
submissions and/or a low level of disease challenge during the study year. Therefore, insufficient data were 
captured to give useful diagnostic information, specifically information regarding the prevention of 
pastuerellosis, which had been the background for this practice-based trial. Future researchers might recruit 
housed lambs to improve capture of mortality cases for diagnostic investigations, which was not the approach 
used here since the aim was to capture data generalisable to pasture-reared lambs. 
 
Lamb growth rates 
Significant between-farm and visit-period differences in growth rate (DLWG) were found, which likely reflect 
differing management practices (e.g. creep feeding of lambs). Across all farms and irrespective of vaccination 
group, the highest mean DLWG (277.4 g/day) was recorded early on, between visits 1 and 2, when lambs were 
between 6 and 12 weeks old, and likely reflects peak milk production of ewes. With the exception of two 
flocks (farms 5 and 6), the mean DLWG over the study period was above 150 g/day. Highest mean DLWG was 
recorded on farm 1 and may be explained in part by that farm’s earlier lambing period, which may be 
associated with reduced parasite and other disease challenges and, most likely, early concentrate feeding of 
lambs prior to weaning. By comparison, lambs born later in the season, grazed in severely disadvantaged areas 
(SDA) (e.g. on farm 5 and 6) and that did not receive supplementary concentrate feeding had a lower mean 
DLWG.  
 
Reduced lamb growth rates can have considerable impacts on flock performance associated with delays in 
finishing time to slaughter, missing the peak in market prices, submission of less-uniform lambs to slaughter, 
increased numbers of lambs kept as stores, and the subsequent effects on ewe lamb fertility and performance 
(Gascoigne and Lovatt, 2015). In this study, mean DLWG reduced over the trial period on all farms and 
decreased considerably post-weaning, prior to visit 4 (98.9 g/day), but improved by visit 5 (122.6 g/day). 
Weaning is a stressful event, with changes to lamb nutrition, social stability and other factors. Reduced 
immunity and increased host susceptibility to infectious and parasitic disease may explain reduced DLWG 
observed at visit 4. However, disease and parasite monitoring were not performed systematically across these 
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parasite burdens in grazing lambs, diagnosing the reasons behind mortalities, and understanding grazing 
management and disease control practices may identify multiple factors associated with reduced growth rates 
around weaning time.  
 
Vaccination was not associated with a significant difference in lamb growth rate. Sample size calculations were 
based on a priori assumptions on mortality differences between vaccinated and unvaccinated lambs. 
Therefore, the lack of statistical significance in analysis of the secondary outcome (DLWG) may reflect a Type I 
statistical error (inadequate sample size to identify a true effect) or a true effect. However, significantly 
reduced growth rates in finishing lambs with severe lung lesions associated with M. haemolytica or P. 
multocida have been identified in a trial with 259 lambs (Daniel et al., 2006), so the sample size of 900 lambs 
presented here may have been sufficient to detect a meaningful effect. A lack of significant differences in 
DLWG was also found in a New Zealand study that tested a multivalent Pasteurella vaccine (Ovipast P Plus, 
MSD Animal Health, 2015) on 9174 lambs from six commercial flocks (Goodwin-Ray et al., 2008). Testing of the 
same Pasteurella spp.-specific vaccine on English sheep flocks was considered but given the additional 
requirements for handling and vaccination costs, and in light of the current vaccine routines and producer 
identified knowledge gap, this trial was instead designed to examine an alteration in timing of commonly 
practiced (post-weaning) vaccination of lambs with a multivalent clostridia and Pasteurella vaccine.  
 
Disease incidence 
An accepted a priori risk was that insufficient disease exposure to detect significant differences in study 
outcomes might occur. Herd immunity (i.e. protection afforded from vaccinated animals within the same 
management group) can affect the ability of studies to detect meaningful between-group differences (Dohoo 
et al., 2009). Therefore, flocks that were not already vaccinating lambs against clostridial disease or 
pasteurellosis, and those with confirmed/suspected disease, were recruited. Furthermore, unvaccinated lambs 
were left within each trial group with the aim of maintaining some disease challenge. Remaining lambs in each 
flock were left unvaccinated as per standard farm practice. Despite this, routine preventive breeding animal 
vaccination on five farms likely reduced disease challenge. Following primary vaccination and pre-lambing 
boosters, datasheets suggest that the vaccine used offers lambs 12 to 16 weeks of colostral-derived antibody 
protection against some clostridial diseases; lamb dysentery, pulpy kidney and tetanus (MSD Animal Health, 
2015). Based on the datasheet advice of unproven, but reported, duration of up to 4 weeks of 
Pasteurella/Mannheimia passive immunity derived from colostrum, it was assumed that pasteurellosis 
challenge was not markedly reduced for trial lambs. All producers participating in the trial perceived a lower 
level of respiratory disease outbreaks in lambs during 2013. Lack of recorded clinical respiratory signs may 
support this view of low disease exposure, although clinical observation is not a sensitive tool. Transthoracic 
ultrasonography is a more sensitive means of diagnosing ovine respiratory disease (Scott and Sargison, 2010), 
but was not applied here due to time and financial constraints. It is not possible to validate producer 
perceptions and trial findings with regional veterinary laboratory diagnostic data (supplementary material) due 
to the very low level of diagnoses, and unknown disease and vaccination status of submitting flocks. Overall, 
there is no strong evidence that suggests 2013 was an unusually low year for pasteurellosis in the region. 
 
Orf cases peaked (11%) at visit 2 and declined considerably 1 month later. Reduced weight gain for up to 5 
weeks after clinical orf lesions has previously been reported in three-week-old lambs (Lovatt et al., 2012). 
However, Lovatt et al. (2012) found no significant growth rate differences between orf affected and unaffected 
lambs aged 7 weeks and over, which concurs with our findings in lambs aged 6 weeks and over. Lameness 
(0.9%) and ocular conditions (3.3%) were lower than those previously reported (2.1% and 6.6%, respectively) 
in younger lambs (Phythian et al., 2013), which may reflect variation in sample age, pathogen exposure, 
management practices, and, potentially, greater veterinary involvement. Gait was assessed as lambs moved 
through handling areas, most frequently mobile systems, at pasture. Thus, lameness levels may represent only 
the most severe cases, and might underestimate true prevalence. Lame lambs, or those with entropion/ocular 
discharge or diarrhoea scour were lighter than unaffected peers. This is the first report providing evidence of a 
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weeks old and above, and highlights the need for early intervention in affected lambs to reduce the animal 
welfare and production impacts associated with these conditions.  
 
Future studies 
A single group of trial lambs was not maintained for both animal welfare and practical reasons. On all farms, 
male and female trial lambs were separated at weaning and remained in a same-sex group of trial lambs. Since 
all farms managed all trial lambs in this way and the statistical methods were capable of taking account of 
individual farm differences, this effect was considered to be limited. Trial timing was based on peak lambing 
dates, logistical considerations, and assumed time to slaughter. One farm unexpectedly dropped out shortly 
before study commencement, and, as a consequence, a later lambing flock was recruited that did not sell 
lambs to slaughter before the trial ended (farm 6). Another flock (farm 1) had sold almost all lambs by the time 
the secondary course of the primary ‘late’ group vaccination was due. However, excluding farms 1 and 6 from 
the dataset made no significant difference to study findings. Whilst a larger sample than suggested by sample 
size estimates had been included to limit the impact of unpredicted issues (e.g. drop-out or unexpected 
disease), selecting farms with closer lambing dates, more similar management practices, as well as recruiting a 
much larger sample, and considering alternative design (e.g. a clustered random trial), could be worthwhile for 
future trials on pasture-managed sheep. Visits were not extended beyond 6 months due to flock management 
and trial financial resources. Future studies might consider only enrolling breeding lambs to facilitate longer-
term evaluation of post-weaning vaccination. Although, findings of such studies may not be generalisable to 
commercial flocks rearing lambs for slaughter.  
 
Conclusions 
Overall, there was a clear trend in reduced mortality rates in grazing lambs that received a multivalent 
clostridia and Pasteurella spp. vaccine course, compared to unvaccinated lambs. No significant effects of pre- 
or post-vaccination on lamb growth rates were found. On one trial farm that did not undertake preventive 
clostridial and Pasteurella breeding animal vaccination, there was strong clinical and gross pathological 
suspicion of Pasteurella and clostridial disease in two lambs, which highlighted the disease risks for 
unvaccinated sheep flocks. Carcase scavenging and decomposition resulted in a very low submission rate of 
lambs found dead at pasture. This lack of veterinary necropsy examination resulted in a loss of valuable data 
on the causes of mortality in grazing lambs, which are likely to vary between flocks and differ between years. 
Whilst there may not be per se a cost benefit for ewe or lamb vaccination every year, best practice 
recommendations for maintaining an annual vaccination regime are based on maintaining ‘herd immunity’. A 
whole farm approach to veterinary flock health planning with specific risk assessment, cost-benefit analysis 
and farm-specific evidence from lamb mortality data, supported by necropsy and diagnostic testing, could help 
to inform the decision to implement a new regime, or to amend the timing of preventive vaccination 
programmes for lambs. 
 
Implications 
Overall, there was evidence to support veterinary advice to implement preventive ewe vaccination on one 
unvaccinated flock (farm 1). This study cannot provide evidence to indicate the benefit of vaccination in flocks 
experiencing severe disease outbreaks associated with Pasteurella spp. There were fewer mortalities in lambs 
that were vaccinated prior to weaning (‘early’ vaccination group). However, this trial cannot provide evidence 
for a ‘one-size fits all’ recommendation for implementing pre-weaning vaccination of lambs in flocks that 
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Table S1 Sheep Surveillance Dashboard 2012–2017 data for number of sheep in Devon submitted for necropsy 
to the regional Animal Plant and Health Agency (APHA) veterinary investigation centre in which Pasteurella 
spp. were diagnosed as cause of death 
Year 





Pneumonia –  
Pastuerella multocida 
2012 2 1 0 
2013 1 2 1 
2014 2 0 0 
2015 1 0 0 
2016 7 0 0 
2017 5 4 1 
Data extracted directly from the publicly available Sheep Disease Surveillance Dashboard: 
https://public.tableau.com/profile/siu.apha#!/vizhome/SheepDashboard_/Overview 
N.B Denominator data on total number of sheep submitted for necropsy over these periods were not provided. 
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